Depreciation of Akebia Therapeutics, Inc. from 31 Dec 2012 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
Akebia Therapeutics, Inc. annual and quarterly Depreciation in USD history and change rate from 31 Dec 2012 to 31 Dec 2025.
  • Akebia Therapeutics, Inc. Depreciation for the quarter ending 31 Mar 2025 was $314,000, a 14% decline year-over-year.
  • Akebia Therapeutics, Inc. annual Depreciation for 2025 was $1,269,000, a 13% decline from 2024.
  • Akebia Therapeutics, Inc. annual Depreciation for 2024 was $1,462,000, a 7.8% decline from 2023.
  • Akebia Therapeutics, Inc. annual Depreciation for 2023 was $1,585,000, a 4.2% decline from 2022.
Source SEC data
View on sec.gov
Depreciation, Annual (USD)
Depreciation, YoY Annual Change (%)
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Change (%)

Akebia Therapeutics, Inc. Annual Depreciation (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $1,269,000 -$193,000 -13% 01 Jan 2025 31 Dec 2025 10-K 26 Feb 2026 2025 FY
2024 $1,462,000 -$123,000 -7.8% 01 Jan 2024 31 Dec 2024 10-K 26 Feb 2026 2025 FY
2023 $1,585,000 -$69,000 -4.2% 01 Jan 2023 31 Dec 2023 10-K 26 Feb 2026 2025 FY
2022 $1,654,000 -$246,000 -13% 01 Jan 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
2021 $1,900,000 -$200,000 -9.5% 01 Jan 2021 31 Dec 2021 10-K/A 28 Aug 2023 2022 FY
2020 $2,100,000 -$100,000 -4.5% 01 Jan 2020 31 Dec 2020 10-K/A 28 Aug 2023 2022 FY
2019 $2,200,000 +$1,300,000 +144% 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
2018 $900,000 +$300,000 +50% 01 Jan 2018 31 Dec 2018 10-K 25 Feb 2021 2020 FY
2017 $600,000 +$300,000 +100% 01 Jan 2017 31 Dec 2017 10-K 12 Mar 2020 2019 FY
2016 $300,000 +$204,000 +212% 01 Jan 2016 31 Dec 2016 10-K 26 Mar 2019 2018 FY
2015 $96,000 +$47,000 +96% 01 Jan 2015 31 Dec 2015 10-K 12 Mar 2018 2017 FY
2014 $49,000 +$48,000 +4800% 01 Jan 2014 31 Dec 2014 10-K 06 Mar 2017 2016 FY
2013 $1,000 +$1,000 01 Jan 2013 31 Dec 2013 10-K 14 Mar 2016 2015 FY
2012 $0 01 Jan 2012 31 Dec 2012 10-K 04 Mar 2015 2014 FY

Akebia Therapeutics, Inc. Quarterly Depreciation (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $314,000 -$50,000 -14% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q1 2024 $364,000 -$34,000 -8.5% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q1 2023 $398,000 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2020 $2,100,000 $600,000 $0 0% 01 Oct 2020 31 Dec 2020 10-K/A 28 Aug 2023 2022 FY
Q3 2020 $2,100,000 $500,000 -$100,000 -17% 01 Jul 2020 30 Sep 2020 10-Q 05 Nov 2020 2020 Q3
Q2 2020 $2,200,000 $500,000 -$100,000 -17% 01 Apr 2020 30 Jun 2020 10-Q 10 Aug 2020 2020 Q2
Q1 2020 $2,300,000 $500,000 +$100,000 +25% 01 Jan 2020 31 Mar 2020 10-Q 05 May 2020 2020 Q1
Q4 2019 $2,200,000 $600,000 +$300,000 +100% 01 Oct 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
Q3 2019 $1,900,000 $600,000 +$400,000 +200% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $1,500,000 $600,000 +$400,000 +200% 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020 2020 Q2
Q1 2019 $1,100,000 $400,000 +$200,000 +100% 01 Jan 2019 31 Mar 2019 10-Q 05 May 2020 2020 Q1
Q4 2018 $900,000 $300,000 +$100,000 +50% 01 Oct 2018 31 Dec 2018 10-K 25 Feb 2021 2020 FY
Q3 2018 $800,000 $200,000 $0 0% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3
Q2 2018 $800,000 $200,000 +$100,000 +100% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019 2019 Q2
Q1 2018 $700,000 $200,000 +$100,000 +100% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019 2019 Q1
Q4 2017 $600,000 $200,000 +$78,000 +64% 01 Oct 2017 31 Dec 2017 10-K 12 Mar 2020 2019 FY
Q3 2017 $522,000 $200,000 +$100,000 +100% 01 Jul 2017 30 Sep 2017 10-Q 08 Nov 2018 2018 Q3
Q2 2017 $422,000 $100,000 +$54,000 +117% 01 Apr 2017 30 Jun 2017 10-Q 08 Aug 2018 2018 Q2
Q1 2017 $368,000 $100,000 +$68,000 +212% 01 Jan 2017 31 Mar 2017 10-Q 09 May 2018 2018 Q1
Q4 2016 $300,000 $122,000 +$112,000 +1120% 01 Oct 2016 31 Dec 2016 10-K 26 Mar 2019 2018 FY
Q3 2016 $188,000 $100,000 +$65,000 +186% 01 Jul 2016 30 Sep 2016 10-Q 08 Nov 2017 2017 Q3
Q2 2016 $123,000 $46,000 +$14,000 +44% 01 Apr 2016 30 Jun 2016 10-Q 08 Aug 2017 2017 Q2
Q1 2016 $109,000 $32,000 +$13,000 +68% 01 Jan 2016 31 Mar 2016 10-Q 09 May 2017 2017 Q1
Q4 2015 $96,000 $10,000 -$6,026 -38% 01 Oct 2015 31 Dec 2015 10-K 12 Mar 2018 2017 FY
Q3 2015 $102,026 $35,000 +$22,000 +169% 01 Jul 2015 30 Sep 2015 10-Q 09 Nov 2016 2016 Q3
Q2 2015 $80,026 $32,000 +$20,026 +167% 01 Apr 2015 30 Jun 2015 10-Q 08 Aug 2016 2016 Q2
Q1 2015 $60,000 $19,000 +$11,000 +138% 01 Jan 2015 31 Mar 2015 10-Q 05 May 2016 2016 Q1
Q4 2014 $49,000 $16,026 +$15,052 +1545% 01 Oct 2014 31 Dec 2014 10-K 06 Mar 2017 2016 FY
Q3 2014 $33,948 $13,000 +$12,974 01 Jul 2014 30 Sep 2014 10-Q 09 Nov 2015 2015 Q3
Q2 2014 $20,974 $11,974 +$11,974 01 Apr 2014 30 Jun 2014 10-Q 11 Aug 2014 2014 Q2
Q1 2014 $9,000 $8,000 +$8,000 01 Jan 2014 31 Mar 2014 10-Q 11 May 2015 2015 Q1
Q4 2013 $1,000 $974 01 Oct 2013 31 Dec 2013 10-K 14 Mar 2016 2015 FY
Q3 2013 $26* 01 Jul 2013 30 Sep 2013 10-Q 10 Nov 2014 2014 Q3
Q2 2013 $0 01 Apr 2013 30 Jun 2013 10-Q 11 Aug 2014 2014 Q2
Q1 2013 $0 01 Jan 2013 31 Mar 2013 10-Q 12 May 2014 2014 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.